RaySearch Laboratories AB (publ) develops software solutions for cancer treatment in Sweden and internationally.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has RaySearch Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RAY B's share price has been volatile over the past 3 months.
7 Day Return
SE Healthcare Services
1 Year Return
SE Healthcare Services
Return vs Industry: RAY B underperformed the Swedish Healthcare Services industry which returned -43.4% over the past year.
Return vs Market: RAY B underperformed the Swedish Market which returned -9.8% over the past year.
Price Volatility Vs. Market
How volatile is RaySearch Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Is RaySearch Laboratories's (STO:RAY B) P/E Ratio After Its Share Price Tanked?
1 week ago | Simply Wall StAre Insiders Selling RaySearch Laboratories AB (publ) (STO:RAY B) Stock?
3 weeks ago | Simply Wall StWhat Is RaySearch Laboratories's (STO:RAY B) P/E Ratio After Its Share Price Tanked?
Is RaySearch Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: RAY B (SEK57.1) is trading above our estimate of fair value (SEK27.05)
Significantly Below Fair Value: RAY B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RAY B is good value based on its PE Ratio (38.8x) compared to the Healthcare Services industry average (39.4x).
PE vs Market: RAY B is poor value based on its PE Ratio (38.8x) compared to the Swedish market (15x).
Price to Earnings Growth Ratio
PEG Ratio: RAY B is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: RAY B is good value based on its PB Ratio (2.8x) compared to the SE Healthcare Services industry average (3.6x).
How is RaySearch Laboratories forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAY B's forecast earnings growth (29.1% per year) is above the savings rate (-0.4%).
Earnings vs Market: RAY B's earnings (29.1% per year) are forecast to grow faster than the Swedish market (8.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RAY B's revenue (12.3% per year) is forecast to grow faster than the Swedish market (4.2% per year).
High Growth Revenue: RAY B's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RAY B's Return on Equity is forecast to be low in 3 years time (15.8%).
How has RaySearch Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RAY B has high quality earnings.
Growing Profit Margin: RAY B's current net profit margins (6.8%) are lower than last year (12.5%).
Past Earnings Growth Analysis
Earnings Trend: RAY B's earnings have grown by 0.7% per year over the past 5 years.
Accelerating Growth: RAY B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RAY B had negative earnings growth (-35.8%) over the past year, making it difficult to compare to the Healthcare Services industry average (-3.8%).
Return on Equity
High ROE: RAY B's Return on Equity (7.1%) is considered low.
How is RaySearch Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: RAY B's short term assets (SEK581.8M) exceed its short term liabilities (SEK357.8M).
Long Term Liabilities: RAY B's short term assets (SEK581.8M) exceed its long term liabilities (SEK200.9M).
Debt to Equity History and Analysis
Debt Level: RAY B's debt to equity ratio (7%) is considered satisfactory.
Reducing Debt: RAY B's debt to equity ratio has reduced from 9.8% to 7% over the past 5 years.
Debt Coverage: RAY B's debt is well covered by operating cash flow (646.4%).
Interest Coverage: RAY B's interest payments on its debt are well covered by EBIT (12.3x coverage).
What is RaySearch Laboratories's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RAY B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RAY B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RAY B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RAY B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: RAY B is not paying a notable dividend for the Swedish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RAY B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Johan Löf (50yo)
Dr. Johan Löf has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Löf serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Löf has been a Di ...
CEO Compensation Analysis
Compensation vs Market: Johan's total compensation ($USD810.86K) is above average for companies of similar size in the Swedish market ($USD501.78K).
Compensation vs Earnings: Johan's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||4.75yrs||no data||0.0029% SEK58.7k|
|Chief Science Officer||4.58yrs||no data||0.070% SEK1.4m|
|General Counsel||2.75yrs||no data||0.0029% SEK58.7k|
|Director of Sales & Marketing||no data||no data||0.0041% SEK82.0k|
|Deputy Chief Executive Officer||4.58yrs||no data||0.052% SEK1.1m|
|Head of Machine Learning||0.25yr||no data||no data|
|President of Raysearch Americas Inc||no data||no data||no data|
Experienced Management: RAY B's management team is considered experienced (4.6 years average tenure).
|Independent Director||15.92yrs||kr250.00k||no data|
|Independent Director||20.25yrs||kr480.00k||3.5% SEK70.4m|
|Chairman of the Board||0.92yr||no data||no data|
|Member of Scientific Advisory Board||17.25yrs||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||no data||no data||3.94% SEK79.1m|
|Member of Scientific Advisory Board||no data||no data||no data|
|Independent Director||2.92yrs||kr250.00k||0.00099% SEK19.9k|
|Independent Director||1.92yrs||kr147.00k||0.020% SEK410.2k|
Experienced Board: RAY B's board of directors are seasoned and experienced ( 15.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
RaySearch Laboratories AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: RaySearch Laboratories AB (publ)
- Ticker: RAY B
- Exchange: OM
- Founded: 2000
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: kr2.009b
- Shares outstanding: 34.28m
- Website: https://www.raysearchlabs.com
Number of Employees
- RaySearch Laboratories AB (publ)
- Sveavägen 44
- Stockholm County
- 111 34
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RAY B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||Jun 2003|
|0GRZ||LSE (London Stock Exchange)||Yes||Class B Shares||GB||SEK||Jun 2003|
|RSLB.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||Jun 2003|
|27R||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||Jun 2003|
|RAYBS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class B Shares||GB||SEK||Jun 2003|
RaySearch Laboratories AB (publ) develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, a oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, and data handling and machine learning. In addition, it provides training courses, as well as customer support services. The company was founded in 2000 and is headquartered in Stockholm, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/08 02:11|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.